Establishment Labs (ESTA) Projected to Post Quarterly Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $50.80 million for the quarter.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.13. The business had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. Establishment Labs’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) earnings per share. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Establishment Labs Stock Performance

Shares of Establishment Labs stock opened at $41.96 on Thursday. The company has a debt-to-equity ratio of 5.72, a current ratio of 3.36 and a quick ratio of 2.05. The firm has a market cap of $1.21 billion, a P/E ratio of -13.54 and a beta of 0.80. The firm has a 50 day simple moving average of $40.21 and a 200 day simple moving average of $36.69. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $50.85.

Analyst Upgrades and Downgrades

A number of research firms have commented on ESTA. Needham & Company LLC reaffirmed a “buy” rating and set a $48.00 target price on shares of Establishment Labs in a report on Friday, June 13th. Citigroup lifted their price target on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 9th. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. Mizuho boosted their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Finally, BTIG Research began coverage on shares of Establishment Labs in a research report on Friday, May 16th. They issued a “buy” rating and a $62.00 price objective on the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Establishment Labs presently has an average rating of “Moderate Buy” and a consensus target price of $54.83.

Institutional Investors Weigh In On Establishment Labs

A hedge fund recently raised its stake in Establishment Labs stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 20.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 57,215 shares of the company’s stock after purchasing an additional 9,557 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.20% of Establishment Labs worth $2,335,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.